168 related articles for article (PubMed ID: 35293763)
1. The predictive value and correlation of β-catenin, CMTM6, and PD-L1 expression in colorectal cancer.
Li B; Wu S; Qiu Z; Zhong X; Chen Z; Luo F; Li J; Liu K
Neoplasma; 2022 May; 69(3):691-699. PubMed ID: 35293763
[TBL] [Abstract][Full Text] [Related]
2. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer.
Peng QH; Wang CH; Chen HM; Zhang RX; Pan ZZ; Lu ZH; Wang GY; Yue X; Huang W; Liu RY
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579737
[TBL] [Abstract][Full Text] [Related]
3. The Predictive Value of CD3+/CD8+ Lymphocyte Infiltration and PD-L1 Expression in Colorectal Cancer.
Liu J; Li J; Luo F; Wu S; Li B; Liu K
Curr Oncol; 2023 Oct; 30(11):9647-9659. PubMed ID: 37999119
[TBL] [Abstract][Full Text] [Related]
4. CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer.
Wu X; Lan X; Hu W; Zhang W; Lai X; Xu S; Li J; Qiu W; Wang W; Xiao J; Wang F; Ding Y; Liang L
Cancer Immunol Immunother; 2021 Nov; 70(11):3235-3248. PubMed ID: 33818637
[TBL] [Abstract][Full Text] [Related]
5. High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer.
Möller K; Blessin NC; Höflmayer D; Büscheck F; Luebke AM; Kluth M; Hube-Magg C; Zalewski K; Hinsch A; Neipp M; Mofid H; Lárusson H; Daniels T; Isbert C; Coerper S; Ditterich D; Rupprecht H; Goetz A; Bernreuther C; Sauter G; Uhlig R; Wilczak W; Simon R; Steurer S; Minner S; Burandt E; Krech T; Perez D; Izbicki JR; Clauditz TS; Marx AH
Acta Oncol; 2021 Sep; 60(9):1210-1217. PubMed ID: 34092167
[TBL] [Abstract][Full Text] [Related]
6. A combination of stromal PD-L1 and tumoral nuclear β-catenin expression as an indicator of colorectal carcinoma progression and resistance to chemoradiotherapy in locally advanced rectal carcinoma.
Takahashi H; Watanabe H; Hashimura M; Matsumoto T; Yokoi A; Nakagawa M; Ishibashi Y; Ito T; Ohhigata K; Saegusa M
J Pathol Clin Res; 2022 Sep; 8(5):458-469. PubMed ID: 35762092
[TBL] [Abstract][Full Text] [Related]
7. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry.
El Jabbour T; Ross JS; Sheehan CE; Affolter KE; Geiersbach KB; Boguniewicz A; Ainechi S; Bronner MP; Jones DM; Lee H
J Clin Pathol; 2018 Jan; 71(1):46-51. PubMed ID: 28667193
[TBL] [Abstract][Full Text] [Related]
9. Molecular and immunological characteristics of patients with CMTM6 low expression colorectal cancer.
Lu ZM; Pan SL; Yuan WL; Feng JL; Tian D; Shang XQ
Medicine (Baltimore); 2023 Dec; 102(50):e36480. PubMed ID: 38115316
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
[TBL] [Abstract][Full Text] [Related]
11. Expression and Clinical Significance of
Shi S; Ma HY; Sang YZ; Ju YB; Liu XY; Zhang ZG
Biomed Res Int; 2022; 2022():8118909. PubMed ID: 35845949
[TBL] [Abstract][Full Text] [Related]
12. Molecular and immune characteristics for lung adenocarcinoma patients with CMTM6 overexpression.
Wang H; Gao J; Zhang R; Li M; Peng Z; Wang H
Int Immunopharmacol; 2020 Jun; 83():106478. PubMed ID: 32278132
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 Overexpression on Tumor-Infiltrating Lymphocytes Related to Better Prognosis of Colorectal Cancer.
Wang JL; Yu T; Sun TT; Feng Y; Xiong H; Fang JY
Clin Lab; 2020 Dec; 66(12):. PubMed ID: 33337839
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
[TBL] [Abstract][Full Text] [Related]
15. Circulating Lymphocytes, PD-L1 Expression on Tumor-infiltrating Lymphocytes, and Survival of Colorectal Cancer Patients with Different Mismatch Repair Gene Status.
Kong P; Wang J; Song Z; Liu S; He W; Jiang C; Xie Q; Yang L; Xia X; Xia L
J Cancer; 2019; 10(7):1745-1754. PubMed ID: 31205530
[TBL] [Abstract][Full Text] [Related]
16. CMTM6 is positively correlated with PD-L1 expression and immune cells infiltration in lung squamous carcinoma.
Shang X; Li J; Wang H; Li Z; Lin J; Chen D; Wang H
Int Immunopharmacol; 2020 Nov; 88():106864. PubMed ID: 32866782
[TBL] [Abstract][Full Text] [Related]
17. Exploring the Expression and Prognosis of Mismatch Repair Proteins and PD-L1 in Colorectal Cancer in a Chinese Cohort.
Han L; Zhang Y; Li L; Zhang Q; Liu Z; Niu H; Hu J; Ding Z; Shi X; Qian X
Cancer Manag Res; 2023; 15():791-801. PubMed ID: 37575316
[TBL] [Abstract][Full Text] [Related]
18. PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer.
Song M; Chen D; Lu B; Wang C; Zhang J; Huang L; Wang X; Timmons CL; Hu J; Liu B; Wu X; Wang L; Wang J; Liu H
PLoS One; 2013; 8(6):e65821. PubMed ID: 23785454
[TBL] [Abstract][Full Text] [Related]
19. Blockage of PD-L1 by FERMT3-mediated Wnt/β-catenin signalling regulates chemoresistance and immune evasion of colorectal cancer cells.
Tang Y; Nan N; Gui C; Zhou X; Jiang W; Zhou X
Clin Exp Pharmacol Physiol; 2022 Sep; 49(9):988-997. PubMed ID: 35672907
[TBL] [Abstract][Full Text] [Related]
20. Differential Expression of CKLF-like MARVEL Transmembrane Domain-Containing Protein 6 and Programmed Cell Death Ligand 1 as Prognostic Biomarkers in Upper Tract Urothelial Carcinoma.
Kdimati S; Christoph C; Glass Ä; Engel N; Dräger DL; Maletzki C; Becker AS; Zimpfer A
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]